1. Cignarelli M., Lamacchia O.. Obesity and kidney disease.
Nutr Metab Cardiovasc Dis 17:2007;757–762.
2. Kang Y.S., Cha J.J., Hyun Y.Y., Cha D.R., Novel C.–C.. chemokine receptor 2 antagonists in metabolic disease: a review of recent developments.
Expert Opin Investig Drugs 20:2011;745–756.
3. Wickman C., Kramer H.. Obesity and kidney disease: potential mechanisms.
Semin Nephrol 33:2013;14–22.
4. Amann K., Benz K.. Structural renal changes in obesity and diabetes.
Semin Nephrol 33:2013;23–33.
5. Kang S.C., Kim B.R., Lee S.Y., Park T.S.. Sphingolipid metabolism and obesity-induced inflammation.
Front Endocrinol 4:2013;1–11.
6. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Jr. Obesity is associated with macrophage accumulation in adipose tissue.
J Clin Invest 112:2003;1796–1808.
7. Kwon H., Pessin J.E.. Adipokines mediate inflammation and insulin resistance.
Front Endocrinol 4:2013;1–13.
8. Tripathy D., Mohanty P., Dhindsa S., Syed T., Ghanim H., Aljada A., Dandona P.. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects.
Diabetes 52:2003;2882–2887.
9. Shi H., Kokoeva M.V., Inouye K., Tzameli I., Yin H., Flier J.S.. TLR4 links innate immunity and fatty acid-induced insulin resistance.
J Clin Invest 116:2006;3015–3025.
10. Lee J.Y., Sohn K.H., Rhee S.H., Hwang D.. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4.
J Biol Chem 276:2001;16683–16689.
11. Takeda K., Akira S.. TLR signaling pathways.
Semin Immunol 16:2004;3–9.
12. Zuany-Amorim C., Hastewell J., Walker C.. Toll-like receptors as potential therapeutic targets for multiple diseases.
Nat Rev Drug Discov 1:2002;797–807.
13. Wu H., Chen G., Wyburn K.R., Yin J., Bertolino P., Eris J.M., Alexander S.I., Sharland A.F., Chadban S.J.. TLR4 activation mediates kidney ischemia/reperfusion injury.
J Clin Invest 117:2007;2847–2859.
14. Cunningham P.N., Wang Y., Guo R., He G., Quigg R.J.. Role of Toll-like receptor 4 in endotoxin-induced acute renal failure.
J Immunol 172:2004;2629–2635.
15. Goldstein D.R., Tesar B.M., Akira S., Lakkis F.G.. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection.
J Clin Invest 111:2003;1571–1578.
16. Liu B., Yang Y., Dai J., Medzhitov R., Freudenberg M.A., Zhang P.L., Li Z.. TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease.
J Immunol 177:2006;6880–6888.
17. Brown H.J., Lock H.R., Wolfs T.G., Buurman W.A., Sacks S.H., Robson M.G.. Toll-like receptor 4 ligation on intrinsic renal cells contributes to the induction of antibody-mediated glomerulonephritis via CXCL1 and CXCL2.
J Am Soc Nephrol 18:2007;1732–1739.
18. Cha J.J., Hyun Y.Y., Lee M.H., Kim J.E., Nam D.H., Song H.K., Kang Y.S., Lee J.E., Kim H.W., Han J.Y., Cha D.R.. Renal protective effects of Toll-like receptor 4 signaling blockade in type 2 diabetic mice.
Endocrinology 154:2013;2144–2155.
19. Stosic-Grujicic S., Cvetkovic I., Mangano K., Fresta M., Maksimovic-Ivanic D., Harhaji L., Popadic D., Momcilovic M., Miljkovic D., Kim J., Al-Abed Y., Nicoletti F.. A potent immunomodulatory compound, (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in nod mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice.
J Pharmacol Exp Ther 320:2007;1038–1049.
20. Stojanovic I., Cuzzocrea S., Mangano K., Mazzon E., Miljkovic D., Wang M., Donia M., Al Abed Y., Kim J., Nicoletti F., Stosic-Grujicic S., Claesson M..
In vitro,
ex vivo and
in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models.
Clin Immunol 123:2007;311–323.
21. Mangano K., Sardesai N., D'Alcamo M., Libra M., Malaguarnera L., Donia M., Bendtzen K., Meroni P., Nicoletti F..
In vitro inhibition of enterobacteria-reactive CD4+CD25-T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027.
Eur J Pharmacol 586:2008;313–321.
22. Bligh E.G., Dyer W.J.. A rapid method of total lipid extraction and purification.
Can J Biochem Physiol 37:1959;911–917.
23. Lee M.H., Song H.K., Ko G.J., Kang Y.S., Han S.Y., Han K.H., Kim H.K., Han J.Y., Cha D.R.. Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue.
Kidney Int 74:2008;890–900.
24. Han S.Y., Kang Y.S., Jee Y.H., Han K.H., Cha D.R., Kang S.W., Han D.S.. High glucose and angiotensin ll increase beta1 integrin and integrin-linked kinase synthesis in cultured mouse podocytes.
Cell Tissue Res 323:2006;321–332.
25. Fasshauer M., Klein J., Neumann S., Eszlinger M., Paschke R.. Isoproterenol inhibits resistin gene expression through a G(S)-protein-coupled pathway in 3T3-L1 adipocytes.
FEBS Lett 500:2001;60–63.
26. Dasu M.R., Jialal I.. Free fatty acids in the presence of high glucose amplify monocyte inflammation via Toll-like receptors.
Am J Physiol Endocrinol Metab 300:2011;E145–E154.
27. Sieber J., Lindenmeyer M.T., Kampe K., Campbell K.N., Cohen C.D., Hopfer H., Mundel P., Jehle A.W.. Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids.
Am J Physiol Renal Physiol 299:2010;F821–F829.
28. Guzik T.J., Mangalat D., Korbut R.. Adipocytokines—novel link between inflammation and vascular function?
J Physiol Pharmacol 57:2006;505–528.
29. Lago F., Dieguez C., Gomez-Reino J., Gualillo O.. Adipokines as emerging mediators of immune response and inflammation.
Nat Clin Pract 3:2007;716–724.
30. Nagai Y., Watanabe Y., Takatsu K.. The TLR family protein RP105/MD-1 complex: a new player in obesity and adipose tissue inflammation.
Adipocyte 2:2013;61–66.
31. Majdalawieh A., Ro H.S.. Regulation of IκBα function and NF-κB signaling: AEBP1 is a novel proinflammatory mediator in macrophages.
Mediators Inflamm 823821:2010;1–27.
32. Schaffler A., Scholmerich J.. Innate immunity and adipose tissue biology.
Trends Immunol 31:2010;228–235.
33. Young B.A., Johnson R.J., Alpers C.E., Eng E., Gordon K., Floege J., Couser W.G., Seidel K.. Cellular events in the evolution of experimental diabetic nephropathy.
Kidney Int 47:1995;935–944.
34. Lin M., Yiu W.H., Li R.X., Wu H.J., Wong D.W., Chan L.Y., Leung J.C., Lai K.N., Tang S.C.. The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy.
Kidney Int 83:2013;887–900.